COSCIENS Biopharma Inc. has seen notable fluctuations in its stock performance recently, with a significant decline over the past week.
This week, COSCIENS Biopharma Inc. (CSCI.TO) experienced a 7.79% decrease in stock price, closing at C$7.10. Despite this recent downturn, the stock has shown impressive growth of 93.99% over the last month and 144.83% year-to-date. Investors are keen to understand the underlying factors affecting this volatility, especially in light of recent financial reports.
Advertisement
Earn cash back with a smarter spending account
Open a KOHO account and start earning on everyday purchases — no annual fee on the base plan.
COSCIENS Biopharma Inc.
CSCI.TO
CSCI.TO
COSCIENS Biopharma Inc.
WealthAwesomeMarket cap
$7.07M
52W high
$14.80
52W low
$1.10
1W change
-7.79%
Beta
1.90
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CSCI's historical volatility
30-Day Vol
575.0%
Annualized
90-Day Vol
353.9%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$8.49
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$7.54 | C$1.04 – C$54.79 |
| 60 trading days | C$8.00 | C$0.48 – C$132.28 |
| 90 trading days | C$8.49 | C$0.27 – C$263.75 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should closely monitor COSCIENS Biopharma's financial updates and market positioning as they navigate the current fluctuations in stock price. Understanding the context behind the numbers may provide insights into the company's future trajectory.
Stock Performance Highlights
COSCIENS Biopharma's stock has experienced a remarkable increase of 144.83% year-to-date despite recent fluctuations.
Bull case
The company's recent financial results show a strong profit margin of 50.7%. This indicates that COSCIENS Biopharma has potential for profitability as it continues to grow in the biopharma sector.
Bear case
The significant drop in stock price relative to its moving averages raises concerns about the company's short-term stability, especially given the recent management cease trade order.
Recent Price Action
COSCIENS Biopharma Inc. closed at C$7.10, reflecting no change in price for the day but a notable decline of 7.79% over the past week. The stock's performance has been volatile, with impressive gains over the past month and year, yet recent price movements raise questions about its short-term viability.
Company News and Developments
Advertisement
While there has been no major news specific to COSCIENS Biopharma this week, recent headlines highlight several financial results, including a net income of $10.8 million reported for Q1 2026, primarily from discontinued operations. This follows a series of quarterly results that reflect ongoing strategic updates and corporate developments. The company also announced a management cease trade order due to potential delays in filing annual financial statements, which may impact investor sentiment.
Technical Picture
From a technical perspective, COSCIENS Biopharma's stock is trading significantly below its 50-day moving average of C$18.68 and its 200-day moving average of C$23.15, indicating a bearish trend. The stock's 52-week range has been C$1.10 to C$14.80, with the current price sitting at approximately 44% of this range. With a beta of 1.90, the stock demonstrates higher volatility compared to the broader market, suggesting that it may be sensitive to market fluctuations.
Insider Activity
No recent insider activity has been reported for COSCIENS Biopharma, indicating that there have been no significant trades by company executives or insiders that could influence investor perception at this time.
Conclusion
As of the last close, COSCIENS Biopharma Inc. remains at C$7.10, reflecting a 1D change of 0.00%. Investors should stay informed about upcoming financial disclosures and corporate developments to gauge the potential impact on stock performance.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
